Biogaia

Quick links to important sections

Biogaia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biogaia

Quick Facts

Property Description
Active ingredient Limosilactobacillus reuteri DSM 17938 (L. reuteri Protectis)
Form Oral drops (oil suspension), Chewable tablets, Powder sachets
Pharmacological class Probiotic, Gut Flora Modifier
Common purpose Promoting and maintaining gastrointestinal wellness
Origin Natural origin (human-sourced bacterial strain)

What Type of Preparation is BioGaia? (Definition and Classification)

BioGaia is an over-the-counter (OTC) microbial dietary supplement that functions as a Probiotic preparation, classifying it within the pharmacological group of Gut Flora Modifiers. This product is not a traditional chemical drug, but a biological agent that uses a live bacterial culture to modulate the internal environment of the gastrointestinal tract. This approach is supported by pharmacological studies that recognize the role of specific microbial strains in promoting digestive health, with the active ingredient having been subject to rigorous assessment under an FDA Investigational New Drug (IND) program in adults.

Composition: The Proprietary Limosilactobacillus reuteri Protectis Strain

The active ingredient in BioGaia is the single, specific, and proprietary strain, Limosilactobacillus reuteri DSM 17938, which is typically marketed as L. reuteri Protectis. This strain is particularly noteworthy because it is clinically recognized for its capacity to colonize the human gut and produce the antimicrobial substance reuterin. The culture is of natural origin, originally isolated from human sources, and is used as a single-strain preparation. The product is available for oral administration in distinct dosage forms, including an oil suspension for oral drops (often preferred for infants) and chewable tablets.

What is the General Purpose of BioGaia? (Mechanism and Benefit)

The overarching purpose of BioGaia is to promote and maintain a stable microbial ecology within the gut. The preparation works by enabling the viable culture to colonize the gastrointestinal lumen, thereby assisting the body in achieving microbial balance. This process of competitive exclusion and the action of metabolites like reuterin aid in sustaining a healthy digestive environment. By supporting this essential biological balance, the product contributes to general gastrointestinal wellness and the maintenance of a well-functioning digestive system, particularly in scenarios that challenge the native gut flora.

Regulatory References

  1. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial

What side effects are possible with Biogaia?

Possible side effects and safety information

The official safety profile for the active ingredient, Limosilactobacillus reuteri DSM 17938, is defined by a primary focus on the Gastrointestinal Disorders system-organ class. The most frequently observed adverse reactions are generally mild and transient.

Officially Documented Adverse Reactions

Category Description
Common Side Effects Flatulence and abdominal discomfort (such as bloating or gas) are classified as Common in regulatory safety documents. These effects may be more noticeable at the beginning of treatment as the gastrointestinal tract adjusts to the new bacterial culture.
Rare/Serious Reactions Systemic infection (bacteremia) is a rare but documented risk considered primarily in specific high-risk populations, underscoring a defined safety constraint for these groups.

Regulatory Safety Considerations

The regulatory profile highlights specific constraints regarding usage in vulnerable patient groups. Official safety notes recommend caution when administering the product to severely immunocompromised individuals, such as those with certain serious underlying diseases or central venous catheters. This caution is based on the documented, though rare, potential for invasive disease when live bacterial cultures are used in these high-risk clinical settings.

Furthermore, government health authorities have issued specific warnings concerning the use of probiotic products in hospitalized preterm infants.

Overdose and Emergency Response

Overdose and When to Seek Help

Official government regulatory information for Biogaia (containing Limosilactobacillus reuteri DSM 17938) generally focuses on immediate emergency response actions rather than detailed dose-related toxicity, reflecting its classification as a probiotic in many regulatory frameworks. Due to the biological nature of the product, detailed clinical overdose presentations, such as those found for chemical drugs, are not typically documented in official prescribing information.

Overdose Scope and Management

Overdose Context Official Regulatory Guidance
Documented Overdose Presentations Symptoms that are serious or life-threatening, such as passing out or trouble breathing.
Vulnerable Populations Specific safety concerns are noted for premature infants, immunocompromised and critically ill patients, and those with central venous catheters due to potential risks like sepsis.
Emergency-Response Action Immediately call a poison control center if an overdose is suspected.
Urgent Medical Help Required If the person has overdosed and is exhibiting serious symptoms such as passing out or trouble breathing, call 911 or local emergency services right away.

Summary of Regulatory Profile

The regulatory profile for overdose emphasizes the need for immediate medical consultation for any suspected intake substantially exceeding the recommended use. The primary mandated action is to contact a poison control center for guidance. The requirement to call emergency services (911) is reserved for situations where severe, life-threatening symptoms are present, serving as the highest severity classification.

Therapeutic Uses of Biogaia

Quick Facts: Primary Therapeutic Domains

  • Infant Digestive Comfort: Helps to reduce episodes of excessive, unexplained crying in infants (infantile colic).
  • Gastrointestinal Support: May assist in managing symptoms of functional abdominal discomfort in children.
  • Diarrhea Management: Supports a shortened duration of acute, infectious diarrhea in pediatric populations.
  • Antibiotic-Associated Diarrhea: Used as an adjunct intervention to help maintain gut balance during antibiotic therapy in children.

Primary Uses and Health Support

Biogaia (containing the probiotic strain Limosilactobacillus reuteri DSM 17938) is primarily used for supporting digestive balance, particularly in infants and children. It is an adjunctive measure that helps to address several common gastrointestinal symptoms.

One of the most established applications is in the care of infants experiencing infantile colic. Routine administration may contribute to a reduction in the time spent crying and overall restlessness associated with this common condition.

In pediatric gastrointestinal support, the supplement may also support the management of acute, watery diarrhea. It may assist in shortening the duration of these episodes. Furthermore, when taken concurrently with antibiotics, it is employed as a supportive strategy to help maintain a balanced intestinal microflora, thereby addressing the incidence of antibiotic-associated diarrhea (AAD) in children.

The therapeutic application of this specific probiotic strain is recognized for its established utility in these functional gastrointestinal domains.

Eligibility and Restrictions for Use

Who can and cannot use BioGaia?

This section outlines the official population eligibility and non-eligibility for this live microbial supplement, strictly based on regulatory documents and authoritative safety guidance.

Eligibility Status Applicable Populations & Conditions
Use Is Permitted Full-term infants from the first day of life (drops), children (chewable tablets for those who can chew), adults, and individuals who are pregnant or breastfeeding [NIH MedlinePlus].
Use Is Prohibited Critically ill hospitalized patients or those with severe immunosuppression/immunodeficiency. This is the paramount non-eligibility rule for live bacteria products due to the documented, heightened risk of systemic infection (bacteremia) [FDA Warning; NIH PMC].
Use Is Not Recommended Hospitalized preterm infants. The U.S. FDA has raised specific concerns and warned against the use of live microbial products in this high-risk population [FDA Warning].
Conditional Use Patients with specific autoimmune diseases, IgA deficiency, or gastrointestinal obstructive diseases were excluded from clinical trials, which establishes restricted use in these comorbidities [ClinicalTrials.gov].

The regulatory profile is structured to establish clear prohibitions for the most vulnerable groups at risk of systemic infection while documenting eligibility for healthy individuals across all standard life stages. No official restrictions are documented based on hepatic or renal impairment.

What should I know about interactions with other medicines?

The official interaction profile for BioGaia (Limosilactobacillus reuteri DSM 17938) is defined by its classification as a live microbial supplement and is focused on the viability of the culture and specific patient population restrictions, rather than traditional pharmacokinetic drug-drug interference. The profile contains no entries for classical metabolic (CYP450) or transporter-mediated interactions.

Interaction Scope

Category Official Regulatory Information
Medicinal product categories with documented interactions Antimicrobial agents (Antibiotics)
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic antagonism (inhibition or destruction of the live microbial culture by the antimicrobial agent).
Timing-based interaction rules (if applicable) Separation of administration from oral antibiotics is advised, typically by one to three hours, to mitigate the risk of bacterial inhibition.
Population-specific interaction notes (if applicable) Increased risk of systemic infection in patients who are immunocompromised or concurrently receiving immunosuppressive agents.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with oral antimicrobial agents may result in a reduction of the live culture's activity due to the antagonistic mechanism.
  • To preserve the bacterial strain, administration must be separated from oral antibiotics by a mandated time period.
  • The use of L. reuteri DSM 17938 carries a documented risk of systemic infection when administered in immunocompromised states.

Connection to the overall interaction profile:

The official regulatory documents define the product's interaction structure around two primary areas: managing the survival of the microbial strain during co-administration with antagonistic substances, and implementing population-specific restrictions for individuals with compromised immune function. The profile does not contain entries for metabolic or transporter-mediated drug-drug interactions typical of systemic chemical medicines.

Mechanism of Action

How Limosilactobacillus reuteri DSM 17938 Works

Limosilactobacillus reuteri DSM 17938 exerts its physiological impact through three primary, concurrent mechanistic domains, with effects that are purely peripheral and dependent on the strain's metabolic activity within the intestinal lumen.

Microbial Stabilization and Targeted Antimicrobial Activity

This mechanism acts locally to inhibit the growth of non-native microorganisms through competitive exclusion and the enzymatic production of the antimicrobial compound, reuterin. This metabolic activity establishes a distinct pattern of microbial community composition and metabolic activity within the lumen.

Visceral Anti-Nociception and Sensory Modulation

This effect is achieved by the strain or its metabolites directly interacting with the enteric nervous system. The mechanism involves the antagonism or downregulation of the TRPV1 ion channel on sensory neurons. By interfering with this nociceptive signaling pathway, the strain effectively modifies the afferent nerve signaling that contributes to visceral sensory input.

Barrier Reinforcement and Local Immune Modulation

The strain influences the physical integrity of the intestinal lining by promoting the upregulation of tight junction proteins like Occludin

and influencing the mucosal immune system. This acts as an immunomodulator, adjusting local cytokine balance to favor anti-inflammatory mediators (e.g., IL-10) over pro-inflammatory signals (e.g., TNF-alpha), thereby reinforcing the epithelial barrier structure and modulating local inflammatory tone.

Dosage and Administration Information

BioGaia, containing Limosilactobacillus reuteri DSM 17938, is an orally administered preparation used according to specific instructions. These instructions define the required dosage, frequency, and preparation steps to ensure the correct use of the live bacterial culture.


Administration Scope

Instruction Detail
Route of administration Oral
Dosing schedule A daily minimum of 1 × 10^8 CFU of L. reuteri Protectis, typically administered as one to two dose units (e.g., 5 drops or 1–2 tablets).
Timing in relation to meals May be taken with or without food.
Preparation requirements The drops formulation must be shaken vigorously for 10 seconds before dispensing to suspend the culture evenly.
Age-group administration rules Drops are intended for use in infants from the first day of life. The product is not intended for premature infants.
Missed-dose rules Not explicitly documented in the standard instructions.
Special procedural conditions Drops must not be administered directly from the bottle into the mouth.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Daily (once daily)
Use-context constraints Must not be mixed with or added to food or liquids warmer than 37 C to preserve the active culture’s viability.

Resulting Procedural Structure

Step sequence:

  • Shake the drops bottle vigorously for 10 seconds before dispensing (if using the drops formulation).
  • Administer the correct daily dose (e.g., 5 drops or 1 tablet) via the oral route.
  • Ensure the dose is not exposed to heat above 37 C.

Connection to the overall use protocol: These administration guidelines enforce a precise, once daily use pattern for the oral preparation. The instructions specify required handling, such as the temperature constraint and shaking the drops, to protect the viable culture and ensure the product is delivered consistently to the intended population.

Recent Clinical Evidence

Research evidence / Overview of Studies for BioGaia

Evidence Base for Infant Digestive Comfort (Infantile Colic)

Research on the Limosilactobacillus reuteri DSM 17938 strain has primarily relied on short-term Randomized Controlled Trials (RCTs) and subsequent large-scale Meta-analyses. These studies were used in research exploring how symptoms change over time by examining the outcomes of the strain compared to an inactive substance (placebo) in young infants. Researchers carefully measured outcomes related to physical discomfort, specifically the daily duration of excessive, unexplained crying and the proportion of infants whose crying episodes were measured as shorter or less frequent. Studies reported patterns observed in some trials where measurements of daily crying time in infants receiving the strain were shorter compared to placebo groups over the four-week observation period.

Evidence Base for Managing Acute Diarrhea in Children

The strain was evaluated in studies exploring the symptom patterns associated with diarrhea in pediatric populations. Research examined the strain as an add-on to standard care, such as rehydration. These trials monitored outcomes describing episodic or acute changes, specifically the duration of the diarrhea episode and measurements related to stool consistency. Studies reported measurements indicating a shorter duration of acute diarrhea in the observed populations compared to control groups receiving rehydration alone. Data show patterns related to how quickly symptoms evolved in the observed groups.

Research Gaps and Uncertainty: What Remains Unclear

Research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain—about the strain's activity. Findings show inconsistency across studies, particularly concerning the symptom patterns observed for functional abdominal discomfort. Data for certain groups remain insufficient, as the vast majority of the high-quality research concentration is in pediatric populations (infants and children), leaving limited information for adults or older adults. Furthermore, long-term outcomes are not fully established, as follow-up durations were limited.

Frequently Asked Questions (FAQ)

Common questions about Biogaia (FAQ)

Q: Is Biogaia the same as other probiotic supplements?

A: Official information indicates that the active component in this preparation is a specific, single, proprietary bacterial strain, L. reuteri DSM 17938. Probiotic preparations are not all the same, and different strains may have distinct research focuses and documented physiological activities.


Q: What is the main difference between Biogaia and Lactobacillus rhamnosus GG?

A: Regulatory-aligned scientific information emphasizes that the benefits of probiotics are strain-specific. This means that two different strains, such as L. reuteri DSM 17938 and Lactobacillus rhamnosus GG, have distinct research profiles and physiological activities.


Q: What happens if I forget to take Biogaia for a day?

A: Official government sources for this product do not provide explicit guidance on how to manage a missed daily dose.


Q: Does Biogaia interact with common prescription medicines?

A: The official interaction profile is focused on specific drug categories, such as antimicrobial agents (antibiotics) and immunosuppressants. The profile states there are no entries for metabolic or transporter-mediated drug-drug interactions.


Q: What does 'Live Active Cultures' mean on the Biogaia packaging?

A: The World Health Organization (WHO) defines probiotics as 'live microorganisms' which, when administered in adequate amounts, may confer a health benefit. The term 'Live Active Cultures' confirms the presence of a viable bacterial culture, a defining characteristic of probiotic preparations.


Q: Is Biogaia approved by health organizations?

A: Official documents classify the product as an over-the-counter (OTC) microbial dietary supplement or food component. This is a regulatory category distinct from the formal 'approval' process required for traditional chemical drugs.


Q: Do studies suggest Biogaia can help with occasional constipation?

A: Research on the L. reuteri DSM 17938 strain has included trials that examined potential benefits for bowel regularity and functional constipation in observed populations.


Q: Does taking Biogaia affect any other supplements I am taking?

A: Official guidance indicates that the interaction profile focuses only on antagonistic medicinal products and does not document specific interactions with other supplements (vitamins, herbs, etc.).


Q: Is the research evidence for Biogaia considered strong?

A: The evidence base relies primarily on short-term Randomized Controlled Trials (RCTs) and Meta-analyses. Research concentration is noted as strong in pediatric populations, but the evidence base for long-term outcomes and some functional symptoms remains inconsistent or limited.


Q: Why does Biogaia have different formulations for different age groups?

A: The product is available in different forms for suitability and ease of administration across life stages. Drops are intended for infants from the first day of life, while chewable tablets are for older children and adults who are able to chew.


Q: Is there a specific time of day that is best to take Biogaia?

A: Official administration instructions mandate a once daily dose. The guidance focuses on the importance of consistent daily intake, and does not specify a superior time of day for administration.


Q: What does official guidance say about using Biogaia?

A: Official guidance defines the product's use by mandating a once daily oral dose and establishing specific safety constraints. It prohibits use in critically ill or severely immunocompromised patients due to a documented infection risk.


Q: How long does it typically take to see any effect from Biogaia?

A: Clinical research has reported measurable changes in outcomes, such as decreased crying time in studies of infant colic. These changes were often observed to occur between the two- to three-week mark of the observation period.


Q: Can Biogaia be used long-term?

A: Because the bacterial strain’s colonization of the gut is transient, the product is designed for consistent daily intake to maintain stable levels. The research overview notes that long-term outcomes have not been fully established in clinical trials.


Q: Is Biogaia generally suitable for people with sensitive guts?

A: Studies have investigated the strain's relationship with digestive tolerance in some populations, but official safety information still notes that initial use may cause transient and mild effects like abdominal discomfort as the body adjusts.


Q: Is it okay to take Biogaia after its expiration date?

A: The official storage and in-use life requirements are established to ensure the viability of the live bacterial culture. Regulatory principles suggest that the product's intended function may be diminished after the expiration date, as the guaranteed viable cell count is not ensured.


Q: Can Biogaia affect blood sugar levels?

A: Clinical studies cited by authoritative sources have investigated the strain's relationship with glucose metabolism and insulin sensitivity in humans, examining its impact on these metabolic markers in some studies.


Q: Why is the active ingredient in Biogaia called Lactobacillus reuteri?

A: Regulatory-aligned content explains that the bacteria was reclassified in 2020 from Lactobacillus reuteri to Limosilactobacillus reuteri. This change was based on updated scientific nomenclature and modern DNA sequencing techniques.


Q: Is it possible to take too much Biogaia?

A: Official safety notes state that the recommended daily dose should not be exceeded. Clinical studies have tested dosages significantly higher than this for the strain, reporting no serious adverse effects.


Q: Does Biogaia contain any artificial sweeteners or colors?

A: Regulatory-aligned warnings state that liquid, powder, or chewable forms of probiotics may contain sugar or aspartame. This information highlights the need for patients with conditions like diabetes or phenylketonuria (PKU) to review the ingredient list.


Q: What is the difference between Biogaia and a prebiotic?

A: Official definitions distinguish the two categories. Probiotics (like BioGaia) are defined as live microorganisms that confer a health benefit, while prebiotics are typically defined as a type of fiber that acts as food to stimulate the growth of beneficial gut bacteria.


Q: What conditions is Biogaia not typically used for?

A: The regulatory focus and research base for this product are specific to gastrointestinal wellness and certain digestive symptoms. It is not indicated for or typically researched for systemic conditions, such as neurological, cardiovascular, or respiratory diseases.


Q: Are there any known issues with taking Biogaia while traveling?

A: Official storage instructions mandate strict temperature constraints (max 25 C / 77 F) and stability requirements (keep dry, keep closed). Non-adherence to these conditions during travel may compromise the viability of the live culture.


Q: Is there evidence about Biogaia for people with IBS?

A: While the main research focus is on infants and children, regulatory-aligned information notes that clinical studies have explored the strain's impact on digestive disorders like IBS and their associated symptoms.


Q: Is it possible for Biogaia to cause a rash or other skin reaction?

A: Official safety information states that symptoms consistent with a very serious allergic reaction (which may include a rash or itching/swelling) have been documented as possible but rare. The guidance specifies that such symptoms warrant attention.

How should Biogaia be stored and disposed of?

The storage and handling requirements for BioGaia Protectis Drops are essential for preserving the live bacterial culture, as detailed in regulatory-aligned labeling.

Scope Item Official Requirement
Storage Temperature Store at room temperature; maximum 25°C (77°F).
Stability/Handling Do not store in the freezer; keep the bottle closed and in a dry place. Avoid contact with fluids like water or saliva.
In-Use Shelf-Life Use within 3 months of first opening the bottle.
Child Safety Keep out of reach of children.
Disposal Instructions Do not flush down a toilet or pour down a drain. Consult a pharmacist or local take-back program for disposal of unused or expired product.

These conditions ensure the product’s viability and adhere to official pharmaceutical handling protocols. The maximum temperature and moisture restrictions are mandatory constraints for product quality.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Biogaia found in:

A-Z Index: